-- ALKS 5461 Demonstrated Consistent Profile of Antidepressant Activity, Safety and Tolerability in Two Phase 3 Studies --
-- New Drug Application for ALKS 5461 Currently Under FDA Review With Target Action Date of Jan. 31, 2019 --
PR Newswire
DUBLIN, Oct. 29, 2018